BioCardia (BCDA) AI Stock Analysis

• Market Cap: $15.06M
• Dividend Yield: N/A
• Average Volume (3M): 993.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -100.00%
• EPS Growth: 60.53%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 10,608,734
• 10 Day Avg. Volume: 2,896,003
• 30 Day Avg. Volume: 993,779
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 166.06
• Enterprise Value/Gross Profit: -22.35
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: $25.00
• Price Target Upside: 1660.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $1.50 ▲(5.63% Upside)

BioCardia's overall stock score is primarily impacted by its weak financial performance and challenging valuation. While there are positive developments in clinical trials and regulatory pathways, the financial instability and bearish technical indicators weigh heavily on the score.

Positive Factors

Regulatory Progress

Regulatory progress in Japan could lead to market entry, expanding BioCardia's reach and potential revenue streams in a new market.

Clinical Trial Success

Successful trial outcomes enhance BioCardia's credibility and support future regulatory approvals, boosting long-term growth prospects.

Partnership Opportunities

Partnerships can provide additional resources and market access, strengthening BioCardia's business model and competitive position.

Negative Factors

Financial Instability

Ongoing financial instability, marked by negative margins, poses risks to sustainability and limits investment in growth initiatives.

Increased R&D Expenses

Rising R&D costs, while necessary for innovation, strain financial resources and may impact short-term cash flow and profitability.

Low Cash Reserves

Low cash reserves necessitate reliance on external financing, which can be risky and limit operational flexibility if not managed well.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia generates revenue primarily through the development and commercialization of its cell therapy products. The company aims to monetize its innovations through clinical trial partnerships, licensing agreements, and potential future product sales. Key revenue streams include funding from clinical trials, grants, and collaborations with other pharmaceutical and biotechnology companies to advance its research and development. Additionally, successful regulatory approvals and subsequent market entry of its therapies could lead to significant sales revenue. Partnerships with healthcare institutions and research organizations also play a crucial role in driving the company's earnings and expanding its market reach.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is weak, with significant challenges in profitability and financial stability. The income statement shows negative EBIT and net income margins, while the balance sheet indicates high leverage risks. Cash flow is negative, relying heavily on financing activities.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.00K	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-431.00K	-372.00K	66.00K	975.00K	375.00K	141.00K
EBITDA	-8.71M	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-8.79M	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	2.09M	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	980.00K	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	745.00K	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	3.98M	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	-1.89M	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-8.46M	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-8.45M	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-4.00K	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	8.01M	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Negative. The current price of 1.42 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.91, and below the 200-day MA of 2.20, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 38.18 is Neutral, neither overbought nor oversold. The STOCH value of 37.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	10.40M	-0.20	-110.35%	―	-62.68%	23.94%
LYRA	48 Neutral	10.64M	-0.22	-805.89%	―	-57.69%	63.76%
ATON	48 Neutral	13.15M	-0.09	―	―	―	48.91%
BRTX	48 Neutral	11.41M	-1.09	―	―	247.62%	-7.66%
BCDA	41 Neutral	$15.06M	―	-737.89%	―	-100.00%	60.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioCardia Corporate Events

BioCardia Partners with CART-Tech for Heart3D™ Imaging

On August 13, 2025, BioCardia, Inc. and CART-Tech, B.V. announced an exclusive development and commercialization agreement for Heart3D™ Fusion Imaging, aimed at enhancing cardiac biotherapeutic delivery and biopsy procedures. The system, which fuses two-dimensional x-ray images with three-dimensional anatomical heart models, is initially intended for research use and may later be approved for standard clinical practice. This partnership leverages both companies’ expertise and intellectual property, with BioCardia securing exclusive distribution rights for biotherapeutic delivery worldwide and cardiac biopsy in the U.S. The collaboration is expected to improve procedural planning and real-time image precision, potentially generating significant revenue if adopted as a standard of care.

The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Updates Regulatory Timeline for Helix System

On August 4, 2025, BioCardia, Inc. announced updates on the regulatory approval timeline for its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter. The company plans to submit a DeNovo 510(k) application for the Helix system to the FDA in Q3 2025, leveraging its safety and performance in numerous clinical studies. Additionally, BioCardia aims to discuss the approval pathway for CardiAMP Cell Therapy for ischemic heart failure with the FDA in Q4 2025, highlighting its previous Breakthrough Designation and clinical trial results. A clinical consultation with Japan’s PMDA is also expected in Q4 2025, potentially facilitating market entry in Japan. These developments could significantly impact BioCardia’s market positioning and provide new opportunities for stakeholders.

The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Submits CardiAMP Therapy for PMDA Review

On July 24, 2025, BioCardia announced the submission of its CardiAMP autologous cell therapy for heart failure to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for clinical consultation. This submission is a crucial step towards potential regulatory approval in Japan, a significant market for advanced heart failure treatments. The consultation will involve a comprehensive review of clinical data from the CardiAMP HF trial, assessing the therapy’s efficacy, safety, and fit within the Japanese healthcare system. Successful alignment with PMDA could lead to market entry in Japan and a subsequent post-marketing study, enhancing BioCardia’s industry positioning and offering new opportunities for collaboration.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.